BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended June 30, 2020 and provides a corporate update.
PR Newswire · 1天前
BioLineRx Granted Australian Patent Number 2014343214 Titled 'Methods of treating acute myeloid leukemia with a FLT3 mutation'
BioLineRx to Report Second Quarter 2020 Results on August 6, 2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended June 30, 2020 on Thursday, August 6, 2020, before the US mark
PR Newswire · 07/31 11:00
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Benzinga · 07/26 13:55
BioLineRx (BLRX) to Report Q2 Earnings: What's in the Cards?
BioLineRx (BLRX) will provide updates on its clinical programs when it releases second-quarter 2020 results.
Zacks · 07/24 17:08
Aclaris (ACRS) Surges: Stock Moves 5.4% Higher
Zacks · 07/08 13:43
Acceleron (XLRN) in Focus: Stock Moves 5.3% Higher
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.